NCT03072537 (CrescNet) is a clinical trial in Obesity, sponsored by University of Leipzig.

Who is sponsoring NCT03072537?

NCT03072537 is sponsored by University of Leipzig.

What condition does NCT03072537 study?

NCT03072537 studies Obesity, Child Development, Growth Disorders.

Is NCT03072537 still recruiting?

NCT03072537 is currently recruiting now. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT03072537: CrescNet

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CrescNet - Growth Monitoring Network

Recruiting now Last updated 7 November 2023

What this trial tests

trial in Obesity in 1,000,000 participants. Currently enrolling.

Timeline

1 January 1998

Primary endpoint
1 January 2028

1 January 2028

Quick facts

Lead sponsor	University of Leipzig
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,000,000
Start date	1 January 1998
Primary completion	1 January 2028
Estimated completion	1 January 2028
Sites	1 location across Germany

Conditions studied

Obesity — all drugs for Obesity →
Child Development — all drugs for Child Development →
Growth Disorders — all drugs for Growth Disorders →

Sponsor

University of Leipzig

Who can join

Under 18, any sex, with Obesity or Child Development. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CrescNet is a network of primary care physicians and pediatricians (n=219) and endocrinological treatment centers (n=33), established in Leipzig in 1998, whose aim is to improve the early detection of growth disorders. Secondary to this clinical aim, epidemiological analyses, for example on secular trends of growth data of children, are performed.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Acceleration of BMI in Early Childhood and Risk of Sustained Obesity.
Geserick M, Vogel M, Gausche R, Lipek T, et al · · 2018 · cited 544× · PMID 30281992 · DOI 10.1056/nejmoa1803527
Age- and weight group-specific weight gain patterns in children and adolescents during the 15 years before and during the COVID-19 pandemic.
Vogel M, Geserick M, Gausche R, Beger C, et al · · 2022 · cited 86× · PMID 34556774 · DOI 10.1038/s41366-021-00968-2
Dynamic alterations in linear growth and endocrine parameters in children with obesity and height reference values.
Kempf E, Vogel M, Vogel T, Kratzsch J, et al · · 2021 · cited 22× · PMID 34386750 · DOI 10.1016/j.eclinm.2021.100977
COVID-19 pandemic and families' utilization of well-child clinics and pediatric practices attendance in Germany.
Vogel M, Beger C, Gausche R, Jurkutat A, et al · · 2021 · cited 16× · PMID 33863371 · DOI 10.1186/s13104-021-05562-3
Data collection on rare bone and mineral conditions in Europe: The landscape of registries and databases.
Priego Zurita AL, Grasemann C, Boarini M, Chapurlat R, et al · · 2023 · cited 7× · PMID 38832910 · DOI 10.1016/j.ejmg.2023.104868
From Childhood to Adolescence: Long-Term Trends in Severe Obesity in German Youth (2002-2023).
Berisha A, Berisha A, Kiess W, Gausche R, et al · · 2025 · cited 2× · PMID 40319873 · DOI 10.1159/000546217
The CrescNet Registry Achondroplasia Module: Real-World Demographic Data and Clinical Outcomes in Untreated and Vosoritide-Treated Individuals.
Mohnike K, Beger C, Gausche R, Hoyer-Kuhn H, et al · · 2026 · PMID 41615893 · DOI 10.1159/000550795
Severity of Congenital Heart Defects Affects Long-Term Somatic Development.
Kiess A, Bimboese P, Gausche R, Beger C, et al · · 2026 · PMID 40042535 · DOI 10.1007/s00246-025-03815-7

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University of Leipzig trials

Trials by the same sponsor.

NCT07155564 — Validation of Energy Expenditure Measures Study · recruiting
NCT06656832 — Peripheral Drivers of Heart Failure Progression - the Prospective PEDAL-HF Study · NA · not yet recruiting
NCT06526013 — Cholesterol Self-testing in Patients Post Acute Coronary Syndrome · NA · recruiting
NCT06420622 — INDIcators for Clarifying the bAckground of exTreme Obesity in childRen · recruiting
NCT06269263 — Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03072537 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leipzig
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing